319 related articles for article (PubMed ID: 30062518)
1. Differential Pricing of Pharmaceuticals: Theory, Evidence and Emerging Issues.
Danzon PM
Pharmacoeconomics; 2018 Dec; 36(12):1395-1405. PubMed ID: 30062518
[TBL] [Abstract][Full Text] [Related]
2. Differential pricing for pharmaceuticals: reconciling access, R&D and patents.
Danzon PM; Towse A
Int J Health Care Finance Econ; 2003 Sep; 3(3):183-205. PubMed ID: 14625999
[TBL] [Abstract][Full Text] [Related]
3. The economics of parallel trade.
Danzon PM
Pharmacoeconomics; 1998 Mar; 13(3):293-304. PubMed ID: 10178655
[TBL] [Abstract][Full Text] [Related]
4. Value-based differential pricing: efficient prices for drugs in a global context.
Danzon P; Towse A; Mestre-Ferrandiz J
Health Econ; 2015 Mar; 24(3):294-301. PubMed ID: 24327269
[TBL] [Abstract][Full Text] [Related]
5. Differential pricing of new pharmaceuticals in lower income European countries.
Kaló Z; Annemans L; Garrison LP
Expert Rev Pharmacoecon Outcomes Res; 2013 Dec; 13(6):735-41. PubMed ID: 24219049
[TBL] [Abstract][Full Text] [Related]
6. Impact of European pharmaceutical price regulation on generic price competition: a review.
Puig-Junoy J
Pharmacoeconomics; 2010; 28(8):649-63. PubMed ID: 20515079
[TBL] [Abstract][Full Text] [Related]
7. Implications of external price referencing of pharmaceuticals in Middle East countries.
Kaló Z; Alabbadi I; Al Ahdab OG; Alowayesh M; Elmahdawy M; Al-Saggabi AH; Tanzi VL; Al-Badriyeh D; Alsultan HS; Ali FM; Elsisi GH; Akhras KS; Vokó Z; Kanavos P
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):993-8. PubMed ID: 26088919
[TBL] [Abstract][Full Text] [Related]
8. Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?
Mestre-Ferrandiz J; Zozaya N; Alcalá B; Hidalgo-Vega Á
Pharmacoeconomics; 2018 Dec; 36(12):1407-1420. PubMed ID: 30198061
[TBL] [Abstract][Full Text] [Related]
9. International trade and determinants of price differentials of insulin medicine.
Helble M; Aizawa T
Health Policy Plan; 2017 Feb; 32(1):1-10. PubMed ID: 27346189
[TBL] [Abstract][Full Text] [Related]
10. [Risk sharing methods in middle income countries].
Inotai A; Kaló Z
Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
[TBL] [Abstract][Full Text] [Related]
11. The hidden cost of low prices: limited access to new drugs in India.
Berndt ER; Cockburn IM
Health Aff (Millwood); 2014 Sep; 33(9):1567-75. PubMed ID: 25201661
[TBL] [Abstract][Full Text] [Related]
12. Pharmaceutical pricing in emerging markets: effects of income, competition, and procurement.
Danzon PM; Mulcahy AW; Towse AK
Health Econ; 2015 Feb; 24(2):238-52. PubMed ID: 24293058
[TBL] [Abstract][Full Text] [Related]
13. Price comparison of high-cost originator medicines in European countries.
Vogler S; Zimmermann N; Babar ZU
Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050
[TBL] [Abstract][Full Text] [Related]
14. An assessment of innovative pricing schemes for the communication of value: is price discrimination and two-part pricing a way forward?
Hertzman P; Miller P; Tolley K
Expert Rev Pharmacoecon Outcomes Res; 2018 Feb; 18(1):5-12. PubMed ID: 29186996
[TBL] [Abstract][Full Text] [Related]
15. Competition and the Reference Pricing Scheme for pharmaceuticals.
Ghislandi S
J Health Econ; 2011 Dec; 30(6):1137-49. PubMed ID: 21937137
[TBL] [Abstract][Full Text] [Related]
16. Cross-national drug price comparisons with economic weights in external reference pricing in Germany.
Mahlich J; Sindern J; Suppliet M
Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):37-43. PubMed ID: 30273062
[TBL] [Abstract][Full Text] [Related]
17. Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
Karnon J; Edney L; Sorich M
Aust Health Rev; 2017 Mar; 41(1):1-6. PubMed ID: 26954612
[TBL] [Abstract][Full Text] [Related]
18. Impact of cross-reference pricing on pharmaceutical prices: manufacturers' pricing strategies and price regulation.
Stargardt T; Schreyögg J
Appl Health Econ Health Policy; 2006; 5(4):235-47. PubMed ID: 17249840
[TBL] [Abstract][Full Text] [Related]
19. Response to: Comment on the implications of external price referencing of pharmaceuticals in Middle East countries.
Kaló Z; Vokó Z; Akhras KS; Kanavos P
Expert Rev Pharmacoecon Outcomes Res; 2016; 16(1):15-6. PubMed ID: 26707267
[No Abstract] [Full Text] [Related]
20. Endogenous versus exogenous generic reference pricing for pharmaceuticals.
Antoñanzas F; Juárez-Castelló CA; Rodríguez-Ibeas R
Int J Health Econ Manag; 2017 Dec; 17(4):413-432. PubMed ID: 28508248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
